CD274 and neoplasm: Recently, the focus of research in this area has been strictly on decreasing the stability of the PD-L1 protein by inactivating GSK3β (phosphorylation at the T180, S9 and S184 sites), thereby regulating T-cell-mediated tumor immunity (66–70).